Stocks Health care UNCY
NASDAQ · Health careUnicycive Therapeutics, Inc. (UNCY)
It posted a net loss of $35.2M. In fiscal 2025 capital spending exceeded operating cash flow by $31.3M. At June 30, 2026 it held $44.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Unicycive Therapeutics, Inc.
- Net worth
- Unicycive Therapeutics, Inc. has a market value (market cap) of $103.1M at the latest share price, and shareholders' equity of $53.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $675K (-29.0% year on year), with a net loss of $30.5M.
- Cash flow
- In fiscal 2025 operations used $31.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Unicycive Therapeutics, Inc.'s next report was expected around October 27, 2026 and is not on file with the SEC yet.
What Unicycive Therapeutics, Inc. does
Unicycive Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker UNCY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.6M | -$1.67 | -$31.3M |
| 2024 | n/a | -$36.7M | -$5.65 | -$28.6M |
| 2023 | $675K | -$30.5M | -$12.91 | -$18.3M |
| 2022 | $951K | -$18.1M | -$12.11 | -$15.7M |
| 2021 | n/a | -$10M | -$8.68 | -$5.8M |
| 2021 | n/a | -$2.3M | -$2.72 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
It paid out $1.1M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2024 | n/a | $1.1M | n/a |
| 2023 | n/a | $900K | n/a |
Latest SEC filings
What Unicycive Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Executive or director change8-KUnicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate and appointed Meredith S. Manning to its board of directors.
- September 28, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- July 2, 2026Other event 8-K
- June 22, 2026Additional proxy material DEFA14A
Insider trades
What the people running Unicycive Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns UNCY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2025 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 80 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 2,802,894 | +1,863,692 |
| BlackRock, Inc. | 1,413,381 | +1,377,478 |
| Vanguard Capital Management LLC | 1,071,481 | +260,051 |
| Octagon Capital Advisors LP | 1,000,000 | 0 |
| Geode Capital Management, LLC | 564,019 | +360,275 |
| Vivo Capital, LLC | 550,000 | -1,239,916 |
| Marshall Wace, Llp | 547,862 | +392,924 |
| Logos Global Management LP | 473,563 | 0 |
| State Street Corp | 450,162 | +370,135 |
| Diametric Capital, LP | 374,132 | +293,770 |
| J. Goldman & Co LP | 327,345 | new |
| Diadema Partners LP | 303,676 | +197,593 |
| Millennium Management LLC | 271,456 | -1,127,892 |
| Dauntless Investment Group, LLC | 214,000 | +66,913 |
| Citigroup Inc | 182,654 | +182,653 |
| Northern Trust Corp | 181,930 | +145,993 |
| Vanguard Portfolio Management LLC | 169,196 | new |
| Susquehanna International Group, Llp | 160,039 | -39,180 |
| Jump Financial, LLC | 153,000 | new |
| Vanguard Fiduciary Trust Co | 148,965 | +47,891 |
Insiders
Questions about UNCY
What does Unicycive Therapeutics, Inc. do?
Unicycive Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as UNCY. Its shares trade on NASDAQ under the ticker UNCY.
What is Unicycive Therapeutics, Inc.'s net worth?
Unicycive Therapeutics, Inc. has a market value (market cap) of $103.1M at the latest share price, and shareholders' equity of $53.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Unicycive Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $35.2M.
When did Unicycive Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 29, 2026.
When is Unicycive Therapeutics, Inc.'s next earnings report?
Unicycive Therapeutics, Inc.'s next report was expected around October 27, 2026 and is not on file with the SEC yet.
Similar companies
Compare UNCY with
Follow UNCY
Get an email when Unicycive Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Unicycive Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.